Improving Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

EP. 1: Standard of Care for Treatment of DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

EP. 2: Prognosis of R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

EP. 3: Treatment in Transplant-ineligible R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

EP. 4: Role of CAR T-cell Therapy in R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

EP. 5: ASCO 2020 Data: CAR T in R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

EP. 6: CAR T in R/R DLBCL: Safety and Patient Selection

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

EP. 7: CD19-Directed Therapies for Treatment of R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

EP. 8: Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

EP. 9: Safety and Efficacy of Oral Agents in R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

EP. 10: Emerging Therapies for R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

EP. 11: Improving Outcomes in Patients With R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

EP. 12: Closing Thoughts on Treatment of R/R DLBCL

ByNathan H. Fowler, MD, MD Anderson Cancer Center,John P. Leonard, MD, Weill Cornell Medicine,Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center,Kami Maddocks, MD, Ohio State University Medical Center

July 15th 2020

Episodes

EP. 1: Standard of Care for Treatment of DLBCL

EP. 2: Prognosis of R/R DLBCL

EP. 3: Treatment in Transplant-ineligible R/R DLBCL

EP. 4: Role of CAR T-cell Therapy in R/R DLBCL

EP. 5: ASCO 2020 Data: CAR T in R/R DLBCL

EP. 6: CAR T in R/R DLBCL: Safety and Patient Selection

EP. 7: CD19-Directed Therapies for Treatment of R/R DLBCL

EP. 8: Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T

EP. 9: Safety and Efficacy of Oral Agents in R/R DLBCL

EP. 10: Emerging Therapies for R/R DLBCL

EP. 11: Improving Outcomes in Patients With R/R DLBCL

EP. 12: Closing Thoughts on Treatment of R/R DLBCL

Trending on OncLive

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

Dr Patel on the Unmet Need in EGFR+ Transformed Small Cell Lung Cancer

Dr Galsky on Systemic Therapy Advances in Muscle-Invasive Bladder Cancer

Dr Cooper on Biomarker Selection for DLL3-Targeted Therapies in ES-SCLC